9.75p+0.50 (+5.41%)29 Nov 2024, 08:18
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Lunglife Ai, INC Fundamentals

Company NameLunglife Ai, INCLast Updated2024-11-29
IndustryDiagnostics & ResearchSectorHealthcare
Shares in Issue30.659 mMarket Cap£2.99 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-$0.21EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0233Debt Equity Ratio0.0037
Asset Equity Ratio1.1419Cash Equity Ratio0.3301
Quick Ratio2.6724Current Ratio2.83
Price To Book Value0.4532ROCE0

Lunglife Ai, INC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Lunglife Ai, INC Company Financials

Assets202320222021
Tangible Assets$389,000.00$566,000.00$766,000.00
Intangible Assets$5.82 m$5.82 m$5.82 m
Investments000
Total Fixed Assets$6.22 m$6.40 m$6.60 m
Stocks000
Debtors$175,000.00$155,000.00$741,000.00
Cash & Equivalents$2.83 m$8.01 m$14.63 m
Other Assets000
Total Assets$9.52 m$15.02 m$21.97 m
Liabilities202320222021
Creditors within 1 year$1.45 m$1.48 m$1.19 m
Creditors after 1 year$163,000.00$396,000.00$651,000.00
Other Liabilities00$174,000.00
Total Liabilities$1.61 m$1.88 m$1.84 m
Net assets$7.91 m$13.14 m$20.13 m
Equity202320222021
Called up share capital$3,000.00$3,000.00$3,000.00
Share Premium$91.27 m$91.27 m$91.26 m
Profit / Loss-$5.41 m-$7.60 m-$7.43 m
Other Equity$7.91 m$13.14 m$20.13 m
Preference & Minorities000
Total Capital Employed$7.91 m$13.14 m$20.13 m
Ratios202320222021
Debt Ratio$0.01$0.03$0.03
Debt-to-Equity$0.01$0.03$0.03
Assets / Equity1.14191.14191.1419
Cash / Equity0.33010.33010.3301
EPS-$0.21-$0.30-$0.39
Cash Flow202320222021
Cash from operating activities-$5.02 m-$5.84 m-$7.54 m
Cashflow before financing-$5.32 m-$6.10 m$16.30 m
Increase in Cash-$364,000.00-$6.13 m$9.09 m
Income202320222021
Turnover$46,000.00$24,000.00$195,000.00
Cost of sales00$96,000.00
Gross Profit$46,000.00$24,000.00$99,000.00
Operating Profit-$5.63 m-$7.74 m-$7.23 m
Pre-Tax profit-$5.41 m-$7.60 m-$7.43 m

Lunglife Ai, INC Company Background

SectorHealthcare
ActivitiesLungLife AI Inc is focused on a developing clinical diagnostic solutions for lung cancer. The Company generates revenue from People's Republic of China and also has its presence in the United States of America.
Latest Interim Date22 Aug 2024
Latest Fiscal Year End Date4 Apr 2024

Lunglife Ai, INC Directors

AppointedNamePosition
2024-04-25Mr. Andrew Norman BotelerNon-Executive Director,Senior Independent Non-Executive Director
2024-10-25Mr. James Renwick McCulloughNon-Executive Director
2023-04-10Ms. Sara Jane BarringtonNon-Executive Director
2024-10-22Dr. Paul Carmelo PaganoExecutive Director,Chief Executive Officer
2024-04-25Mr. Gordon Roy DavisNon-Executive Director,Chairman
2024-10-22Mr. David Mark AndersonExecutive Director,Chief Financial Officer and Company Secretary

Lunglife Ai, INC Contact Details

Company NameLungLife AI Inc
Address850 New Burton Road, Suite 201, Dover, 19904
Telephone+1 805 409-9868
Websitehttps://www.lunglifeai.com

Lunglife Ai, INC Advisors